期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 126, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2020.110012
关键词
Heart failure; Astragaloside IV; Traditional Chinese medicine; Pharmacological effect
资金
- National Natural Science Foundation of China [81773726]
- Shanghai Science and Technology Innovation Action Plan [19401900100]
- National Science and Technology Major Project [2018ZX09711002-003-015, 2018ZX09J18110-003-001]
Heart failure (HF) has become a worldwide public health problem that seriously threatens human's health. Due to multi-target effect, traditional Chinese medicine (TCM) has unique advantages in this field. Chinese herb-derived active components would provide valuable candidate compounds for new drug development. Astragaloside IV(AS-IV) is a main effective ingredient of Astragalus membranaceus, a commonly used Chinese patent medicine for the patients with chronic heart failure(CHF). Our aim is to review the recent progresses of AS-IV in HF, and provide potential evidence for its clinical application. Data showed that AS-IV could protect myocardial ischemia, regulate sarcoplasmic reticulum Ca2+ pump, promote angiogenesis, improve energy metabolism, inhibit cardiac hypertrophy and fibrosis, reduce myocardial cell apoptosis, etc, which are direct or indirect involved in the beneficial effects of AS-IV in rodents or cellular models of HF. AS-IV or its derivatives may act as a potential therapeutic drug in the clinical treatment of HF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据